How to Sell a Medical Practice (2026): 4x-12x EBITDA & PE Buyers

Selling a medical practice is one of the most regulatory-complex small-business sale processes. Beyond standard M&A diligence, sellers must navigate Stark Law (physician self-referral prohibitions), Anti-Kickback Statute, state licensure transfer (which can take 6-12 months in some states), Medicare/Medicaid provider agreement transfer, malpractice tail coverage requirements, and patient-record HIPAA considerations. The process is rewarding (multiples reach 8-12x EBITDA for in-demand specialties) but demands physician-experienced advisors.

This guide covers the practical sale process: 2026 valuations by specialty, buyer types (PE-backed physician groups, hospital systems, larger practices), regulatory considerations, 12-month preparation playbook, and post-close transition expectations. Physician practices have become a major PE roll-up sector since 2018, with active platforms in dermatology, ophthalmology, gastroenterology, orthopedics, dental, vet, and more. For physician-owners considering sale, the path to maximizing value requires understanding both the medical practice fundamentals and the PE-buyer playbook.

“Selling a medical practice in 2026 is fundamentally different from selling any other small business. The regulatory complexity alone adds 30-50% to the typical process timeline — but the multiples PE pays for the right specialties make the work worth it.”

Key Takeaways

• Medical practice multiples 2026: 4-8x EBITDA most specialties; 8-12x for PE-favored high-demand specialties.
• Three buyer types: PE-backed physician groups (most active), hospital systems, larger practices/groups.
• Active PE roll-up specialties: dermatology, ophthalmology, gastroenterology, orthopedics, dental, vet, plastic surgery, pain management.
• Regulatory complexity: Stark Law, Anti-Kickback, state licensure transfer, Medicare/Medicaid provider agreements, HIPAA, malpractice tail.
• Preparation 12+ months pre-sale produces 20-40% higher proceeds: optimize productivity, document referral patterns, address staff retention.
• Process timeline: 9-18 months from advisor engagement to close (longer than standard M&A due to regulatory work).
• Post-close: physicians typically remain 3-5+ years as employed providers + equity holders in the platform.
• Critical valuation drivers: payor mix, provider productivity, referral patterns, ancillary revenue (in-office surgery, imaging, lab), real estate ownership.

Medical practice valuation: 2026 multiples by specialty

For 2026 sell a plastic surgery practice at 3x-10x EBITDA with cosmetic-cash mix, owner-MD brand dependency, and named buyers (SkinSpirit, Sono Bello, Skytale), see our reference.

For 2026 how to buy a veterinary practice with 4x-12x range, corporate consolidator competition (Mars, NVA, Pathway), and SBA 7(a) financing, see our guide.

For 2026 how to sell a medical practice with 5x-12x EBITDA by specialty, named PE consolidators (Optum, USPI), and Stark / Anti-Kickback diligence, see our reference guide.

For 2026 how to sell a fertility clinic with 6x-14x EBITDA multiples and named MSO buyers (Inception, Pinnacle, US Fertility, Kindbody), see our reference guide.

For 2026 how to sell a cardiology practice with 6x-12x EBITDA multiples and named MSO buyers (US Heart & Vascular, CVA, US Cardiology Partners), see our guide.

For 2026 optometry acquisition playbook with 3x-9x multiple bands, vision-plan diligence, and SBA 7(a) financing, see our reference guide.

For 2026 how to sell a wound care business with 5x-11x EBITDA multiples and named buyers (Healogics, Restorix, Vohra), see our reference guide.

For 2026 sell my home health business with no broker fee with 60-120 day close and $0 seller fee buyer-paid advisory, see our reference.

For 2026 how to sell an imaging center with 4x-12x EBITDA by modality and named buyers (RadNet, Akumin, SimonMed, US Radiology), see our guide.

For 2026 how to sell an orthopedic practice with multiples by subspecialty / ASC and named MSO buyers (US Orthopaedic Partners, HOPCo, Resurgens), see our guide.

For 2026 dermatology MSO sale playbook with 5x-14x EBITDA multiples and named buyers (Schweiger, Forefront, Advanced, Pinnacle), see our guide.

For 2026 how to sell a dialysis business with 5x-11x EBITDA multiples and the duopoly (DaVita + Fresenius) plus emerging buyers, see our guide.

For the 2026 inventory of private equity in dermatology with 35+ named PE-backed MSOs, see our buyer-tracker guide.

For 2026 healthcare business valuation across practices, ASCs, home health, urgent care, and billing, see our reference guide.

For 2026 urology practice multiples, MSO playbook, and named PE buyers, see our selling a urology practice guide.

Multiples vary widely by specialty. Below are 2026 typical ranges for healthy, growing practices being acquired by PE-backed physician groups or larger practices.

Three primary buyer types

Medical practice sales typically go to one of three buyer types. Each has different process, valuations, and post-close physician expectations.

1. PE-backed physician groups

PE-backed physician groups are the dominant buyer for in-demand specialties. Strategy: acquire platform practice ($5-25M EBITDA), bolt on smaller practices over 3-5 years, exit to larger PE or strategic at higher multiple. Valuations: 8-12x for first add-ons in a new region; 6-8x for later add-ons in saturated regions. Post-close: physician typically becomes W-2 employee of platform + holds 10-20% equity in platform (tax-deferred via rollover).

2. Hospital systems

Hospital systems acquire practices for service-line expansion and referral capture. Valuations: 3-6x EBITDA typically (below PE because hospital systems can’t apply PE-scale operational improvements). Post-close: physician typically becomes hospital-employed; loses owner autonomy and equity upside. Better for specialties without active PE consolidation (cardiology, primary care historically).

3. Larger practices and groups

Independent larger practices and groups acquire smaller competitors for geographic expansion and ancillary revenue. Valuations: 4-7x EBITDA. Less institutional process; often negotiated bilateral deals. Post-close: physician integrates into existing group; potentially equity partnership if group is partnership-structured.

Regulatory complexity: what makes medical sales different

Medical practice sales involve regulatory considerations that don’t exist in other industries. These add 6-12 months to the typical sale timeline and require physician-experienced legal counsel.

• Stark Law (Self-Referral Prohibition). Physicians can’t refer Medicare/Medicaid patients to entities with which they have a financial relationship. Sale structures must comply with safe harbors.
• Anti-Kickback Statute. Prohibits remuneration for healthcare referrals. Deal structure (especially earnouts tied to referrals) needs careful review.
• State Licensure Transfer. Many states require provider re-credentialing under new ownership (6-12 months in some states; weeks in others).
• Medicare/Medicaid Provider Agreements. Transfer requires CMS approval; typically 3-9 months.
• HIPAA and Patient Records. Patient consent often required for record transfer; complex for large practices with thousands of patients.
• Malpractice Tail Coverage. Selling physician must obtain ‘tail’ coverage for claims arising from pre-close activities ($25K-$200K typical cost).
• Contract Assignability. Insurance contracts, lease agreements, vendor agreements often have change-of-control restrictions.
• Antitrust review. Larger deals ($101M+ HSR threshold) require FTC notification. Some specialty markets have anti-consolidation pressure.

Valuation drivers: what moves multiples up

Six factors move medical practice multiples within their specialty range. Optimizing these 12-24 months pre-sale produces 20-40% higher valuation.

1. Payor mix. Commercial payors (BCBS, UHC, Aetna, Cigna) command higher rates than Medicare/Medicaid. Practices with 60%+ commercial mix get premium multiples.
2. Provider productivity. Production per provider (collections, RVUs, patient volume) above specialty median commands premium.
3. Referral patterns. Stable inbound referral relationships from PCPs, specialists, hospitals. Document these clearly for buyer diligence.
4. Ancillary revenue. In-office surgery, imaging (PET, MRI, ultrasound), lab work, infusion services, pharmacy. Each ancillary stream adds material EBITDA and multiple.
5. Real estate ownership. Physician-owned real estate often sold separately (sale-leaseback) for additional value beyond practice EBITDA.
6. Provider depth. 3+ providers reduces key-person risk; 5+ providers attracts PE platforms; single-provider practices command lower multiples.

Pre-sale preparation: 12-month playbook

Preparation 12+ months in advance materially improves outcomes. Below is the canonical timeline.

1. 12-18 months out: Engage healthcare-experienced M&A advisor for valuation benchmark. Optimize payor mix (drop low-paying contracts). Address provider productivity gaps. Document referral patterns systematically.
2. 9-12 months out: Clean up financials (GAAP-compliant, monthly close discipline). Implement clean Chart of Accounts separating practice income from owner-discretionary expenses. Address pending litigation or regulatory issues.
3. 6-9 months out: Engage healthcare M&A attorney for regulatory pre-clearance. Document staff retention strategy. Sell-side QoE for $5M+ EBITDA practices.
4. 3-6 months out: Marketing teaser/CIM preparation. Initial buyer outreach to PE platforms and larger practices.
5. 3-0 months out: LOI process. Diligence support. Regulatory pre-filing where applicable.
6. Post-LOI to close: Full due diligence (90-150 days for medical; longer than standard M&A). State licensure work. CMS provider transfer.

Post-close: what physicians can expect

Post-close physician role varies dramatically by buyer type. Understanding the post-close path is critical for choosing the right buyer.

Specialties most attractive to PE in 2026

Five specialty categories have strongest PE consolidation activity in 2026. Sellers in these specialties enjoy multiple competing platforms and premium valuations.

• Dermatology. 5+ active platforms (DermCare Management, Forefront Dermatology, Schweiger Dermatology Group, Pinnacle Dermatology, others). 8-12x EBITDA typical.
• Ophthalmology. EyeCare Partners, MyEyeDr., Acuity Eyecare Group. Optometry consolidation also active.
• Gastroenterology. GI Alliance, US Digestive Health, One GI. ASC ownership critical to valuations.
• Dental DSOs. Heartland Dental, Aspen Dental, Pacific Dental Services, Smile Brands. Mature market; multiples 5-9x.
• Veterinary. Highest multiples (8-15x EBITDA). Mars/Banfield, NVA, BluePearl, VCA dominate.

Pricing your practice: realistic expectations

For a typical 3-provider specialty practice at $3M EBITDA, here’s the practical pricing range by specialty. Use as benchmark; specific deals vary based on geography, payor mix, ancillary revenue.

Common medical practice sale mistakes

Five recurring mistakes destroy value in medical practice sales. Each is correctable with proper preparation.

• Engaging non-healthcare M&A advisor. Generic M&A advisors don’t understand Stark Law, payor mix dynamics, or PE roll-up specialty mechanics. Use specialists.
• Underestimating regulatory timeline. Medicare/state licensure can add 6-9 months. Plan accordingly.
• Aggressive add-back schedule. Buyers and QoE providers heavily scrutinize physician compensation, RVU calculations, and ancillary income. Conservative add-backs win.
• Not running competitive process. Bilateral negotiation with one PE platform typically produces 15-25% lower outcomes than running 3-5 competing platforms.
• Ignoring post-close employment terms. Buyer’s standard employment contract may have restrictive non-competes, low base + production bonus, weak benefits. Negotiate carefully.

Independent practice vs PE platform: should I sell or stay?

Some physicians fight the PE consolidation trend and remain independent. The right answer depends on specialty, age, and personal priorities.

• Sell to PE when: approaching retirement (5-10 years out), want partial liquidity + continued work, sector has active PE consolidation, want larger group’s administrative support.
• Stay independent when: mid-career physician (15+ years to retirement), enjoy operational control, sector has limited PE activity, willing to accept administrative burden.
• Wait and see: 5-10 year horizon, monitor specialty consolidation, optimize practice for eventual sale, maintain optionality.

Conclusion

Selling a medical practice in 2026 produces 4-12x EBITDA depending on specialty. PE-backed physician groups dominate the active consolidation specialties (dermatology, ophthalmology, GI, dental, vet); hospital systems and larger practices acquire in less-consolidated specialties (primary care, cardiology, OB/GYN). Regulatory complexity adds 6-12 months to the timeline; preparation 12+ months in advance produces 20-40% higher proceeds. CT Acquisitions works with PE-backed physician groups — the buyer pays our fee at close.

Frequently Asked Questions

How much is a medical practice worth?

Depends on specialty and PE consolidation activity. 2026 typical multiples: dermatology 8-12x EBITDA, ophthalmology 8-11x, GI 7-10x, orthopedics 7-10x, dental 6-9x, primary care 4-6x, vet 8-15x. For a 3-provider specialty practice at $3M EBITDA, that’s $12M-$36M enterprise value depending on specialty and quality factors.

Who buys medical practices?

Three primary buyer types: (1) PE-backed physician groups — most active in dermatology, ophthalmology, GI, dental, vet, ortho, plastic surgery; pay highest multiples (8-12x). (2) Hospital systems — acquire for service-line expansion and referral capture; pay 3-6x. (3) Larger practices/groups — acquire for geographic expansion and ancillary revenue; pay 4-7x.

How long does it take to sell a medical practice?

9-18 months from advisor engagement to close, longer than standard M&A due to regulatory complexity. Stages: 6-9 months preparation + 2-3 months marketing/LOI + 4-6 months due diligence + regulatory transfer (state licensure, Medicare provider agreement, malpractice tail). Plan 12+ months for serious preparation work pre-engagement.

What is Stark Law and how does it affect practice sales?

Stark Law prohibits physicians from referring Medicare/Medicaid patients to entities with which they have a financial relationship (with safe harbor exceptions). Affects sale structures: earnouts tied to referrals, post-close compensation structures, joint ventures with hospitals all need Stark compliance review. Healthcare M&A counsel essential for navigating.

What’s the difference between PE-backed and hospital acquisition?

PE-backed group: physician becomes W-2 employee + holds platform equity (10-20%); typical 8-12x EBITDA valuation; aggressive consolidation strategy; physician retains operational input. Hospital system: physician becomes hospital employee; typical 3-6x EBITDA valuation; loses owner autonomy and equity upside; focus on service-line integration and referral capture.

What is a DSO (Dental Service Organization)?

A DSO is a management services organization that provides non-clinical management to dental practices (administration, marketing, finance, HR, IT, supply chain) in exchange for management fees. PE-backed DSOs acquire equity in clinical practices (often via Management Services Agreement structures in restricted states). Major DSOs: Heartland Dental ($2B+ revenue), Aspen Dental, Pacific Dental Services, Smile Brands. Multiples: 6-9x EBITDA typical.

Do I have to stay after selling my practice to PE?

Typically yes, 3-5+ years as W-2 employee with production-based compensation. PE platforms require physician continuity to retain patients and referrals. Employment contracts typically include: base salary + production bonus, equity vesting (10-20% platform equity, 4-5 year vest), restrictive covenants (non-compete, non-solicitation), and right of first refusal on subsequent practice equity transactions.

What is malpractice tail coverage?

Tail coverage extends malpractice insurance to cover claims arising from pre-close clinical activities that may be filed after the sale closes. Required because most claims-made policies stop covering past activities once premium payments end. Cost: $25K-$200K depending on specialty, claim history, and policy structure. Usually negotiated as buyer-paid or split-cost in the LOI.

How can I maximize my practice’s valuation?

Six levers: (1) optimize payor mix (60%+ commercial), (2) increase provider productivity above specialty median, (3) document inbound referral patterns systematically, (4) add ancillary revenue (in-office surgery, imaging, lab, infusion), (5) own practice real estate (sell-leaseback adds value), (6) build provider depth (3+ providers reduces key-person risk; 5+ attracts PE platforms). Each lever moves multiples 0.5-1.5x within specialty range.

Should I sell my real estate with my practice?

Usually no, sell separately. Real estate-physician separation produces: (1) sale-leaseback structure where physician retains real estate ownership + receives lease income, (2) potential 10-15% additional cap-rate-based value, (3) cleaner buyer diligence (buyer focused on practice operations, not real estate). Common structure: practice sells at EBITDA multiple; real estate sells at separate cap rate.

What’s the difference between MSO and practice acquisition?

Practice acquisition: PE platform acquires clinical practice equity directly; physician becomes employee + platform equity holder. MSO (Management Services Organization) structure: physician retains clinical practice ownership but contracts with MSO for management services; MSO can hold equity in non-clinical practice operations. Used in states (CA, NY, NJ, TX) with corporate practice of medicine restrictions limiting non-physician practice ownership.

Why work with CT Acquisitions to sell my practice?

CT Acquisitions works with PE-backed physician groups actively acquiring practices across consolidation-active specialties. We can match your practice to the specific PE platforms most likely to fit your specialty, geography, and size. The buyer pays our fee at close — the seller pays nothing. No exclusivity, no contracts. Most engagements close in 9-15 months given medical regulatory timelines.